nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—kidney cancer—melanoma	0.325	1	CtDrD
Everolimus—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.297	0.58	CiPCiCtD
Everolimus—P-Glycoprotein Inhibitors—Vemurafenib—melanoma	0.215	0.42	CiPCiCtD
Everolimus—CYP3A4—Temozolomide—melanoma	0.0159	0.576	CbGbCtD
Everolimus—CYP3A4—Vemurafenib—melanoma	0.00869	0.316	CbGbCtD
Everolimus—MTOR—leg—melanoma	0.00329	0.177	CbGeAlD
Everolimus—CYP3A4—Docetaxel—melanoma	0.00298	0.108	CbGbCtD
Everolimus—MTOR—hindlimb—melanoma	0.00294	0.158	CbGeAlD
Everolimus—MTOR—appendage—melanoma	0.00252	0.135	CbGeAlD
Everolimus—MTOR—blood vessel—melanoma	0.0014	0.0754	CbGeAlD
Everolimus—MTOR—neck—melanoma	0.001	0.0539	CbGeAlD
Everolimus—FKBP1A—neck—melanoma	0.000903	0.0485	CbGeAlD
Everolimus—Sirolimus—FGF2—melanoma	0.000749	0.63	CrCbGaD
Everolimus—MTOR—eye—melanoma	0.000747	0.0401	CbGeAlD
Everolimus—MTOR—retina—melanoma	0.00074	0.0398	CbGeAlD
Everolimus—FKBP1A—eye—melanoma	0.000672	0.0361	CbGeAlD
Everolimus—FKBP1A—retina—melanoma	0.000666	0.0358	CbGeAlD
Everolimus—MTOR—skin of body—melanoma	0.00065	0.0349	CbGeAlD
Everolimus—MTOR—mammalian vulva—melanoma	0.000592	0.0318	CbGeAlD
Everolimus—FKBP1A—skin of body—melanoma	0.000584	0.0314	CbGeAlD
Everolimus—FKBP1A—mammalian vulva—melanoma	0.000533	0.0286	CbGeAlD
Everolimus—MTOR—head—melanoma	0.000424	0.0228	CbGeAlD
Everolimus—FKBP1A—head—melanoma	0.000381	0.0205	CbGeAlD
Everolimus—MTOR—lymph node—melanoma	0.000297	0.0159	CbGeAlD
Everolimus—FKBP1A—lymph node—melanoma	0.000267	0.0143	CbGeAlD
Everolimus—Temsirolimus—ABCB1—melanoma	0.000119	0.1	CrCbGaD
Everolimus—Tacrolimus—ALB—melanoma	0.00011	0.0926	CrCbGaD
Everolimus—Sirolimus—ABCB1—melanoma	0.000105	0.0883	CrCbGaD
Everolimus—Tacrolimus—ABCB1—melanoma	0.000105	0.0883	CrCbGaD
Everolimus—Angiopathy—Temozolomide—melanoma	5.13e-05	0.000818	CcSEcCtD
Everolimus—Mental disorder—Carmustine—melanoma	5.12e-05	0.000818	CcSEcCtD
Everolimus—Immune system disorder—Temozolomide—melanoma	5.11e-05	0.000815	CcSEcCtD
Everolimus—Mediastinal disorder—Temozolomide—melanoma	5.09e-05	0.000813	CcSEcCtD
Everolimus—Erythema—Carmustine—melanoma	5.09e-05	0.000813	CcSEcCtD
Everolimus—Malnutrition—Carmustine—melanoma	5.09e-05	0.000813	CcSEcCtD
Everolimus—Cough—Bleomycin—melanoma	5.09e-05	0.000812	CcSEcCtD
Everolimus—Chills—Temozolomide—melanoma	5.07e-05	0.000809	CcSEcCtD
Everolimus—Dehydration—Docetaxel—melanoma	5.05e-05	0.000806	CcSEcCtD
Everolimus—Ill-defined disorder—Dactinomycin—melanoma	5.05e-05	0.000806	CcSEcCtD
Everolimus—Anaemia—Dactinomycin—melanoma	5.03e-05	0.000802	CcSEcCtD
Everolimus—Liver function test abnormal—Docetaxel—melanoma	5.02e-05	0.000801	CcSEcCtD
Everolimus—Vomiting—Vemurafenib—melanoma	5e-05	0.000797	CcSEcCtD
Everolimus—Alopecia—Temozolomide—melanoma	4.99e-05	0.000797	CcSEcCtD
Everolimus—Dry skin—Docetaxel—melanoma	4.98e-05	0.000795	CcSEcCtD
Everolimus—Myalgia—Bleomycin—melanoma	4.97e-05	0.000793	CcSEcCtD
Everolimus—Chest pain—Bleomycin—melanoma	4.97e-05	0.000793	CcSEcCtD
Everolimus—Abdominal pain upper—Docetaxel—melanoma	4.96e-05	0.000792	CcSEcCtD
Everolimus—Rash—Vemurafenib—melanoma	4.95e-05	0.000791	CcSEcCtD
Everolimus—Mental disorder—Temozolomide—melanoma	4.95e-05	0.00079	CcSEcCtD
Everolimus—Dermatitis—Vemurafenib—melanoma	4.95e-05	0.00079	CcSEcCtD
Everolimus—Back pain—Carmustine—melanoma	4.92e-05	0.000786	CcSEcCtD
Everolimus—Headache—Vemurafenib—melanoma	4.92e-05	0.000786	CcSEcCtD
Everolimus—Malnutrition—Temozolomide—melanoma	4.92e-05	0.000785	CcSEcCtD
Everolimus—Erythema—Temozolomide—melanoma	4.92e-05	0.000785	CcSEcCtD
Everolimus—Breast disorder—Docetaxel—melanoma	4.91e-05	0.000784	CcSEcCtD
Everolimus—Discomfort—Bleomycin—melanoma	4.91e-05	0.000783	CcSEcCtD
Everolimus—Malaise—Dactinomycin—melanoma	4.91e-05	0.000783	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Docetaxel—melanoma	4.89e-05	0.000781	CcSEcCtD
Everolimus—Leukopenia—Dactinomycin—melanoma	4.87e-05	0.000777	CcSEcCtD
Everolimus—Nasopharyngitis—Docetaxel—melanoma	4.86e-05	0.000775	CcSEcCtD
Everolimus—Dysgeusia—Temozolomide—melanoma	4.82e-05	0.000769	CcSEcCtD
Everolimus—Vision blurred—Carmustine—melanoma	4.8e-05	0.000766	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Docetaxel—melanoma	4.79e-05	0.000765	CcSEcCtD
Everolimus—Tremor—Carmustine—melanoma	4.77e-05	0.000761	CcSEcCtD
Everolimus—Oedema—Bleomycin—melanoma	4.76e-05	0.00076	CcSEcCtD
Everolimus—Back pain—Temozolomide—melanoma	4.76e-05	0.00076	CcSEcCtD
Everolimus—Infection—Bleomycin—melanoma	4.73e-05	0.000755	CcSEcCtD
Everolimus—Anaemia—Carmustine—melanoma	4.71e-05	0.000751	CcSEcCtD
Everolimus—Dysphagia—Docetaxel—melanoma	4.7e-05	0.000749	CcSEcCtD
Everolimus—Agitation—Carmustine—melanoma	4.68e-05	0.000747	CcSEcCtD
Everolimus—Nausea—Vemurafenib—melanoma	4.67e-05	0.000745	CcSEcCtD
Everolimus—Thrombocytopenia—Bleomycin—melanoma	4.66e-05	0.000744	CcSEcCtD
Everolimus—Vision blurred—Temozolomide—melanoma	4.64e-05	0.00074	CcSEcCtD
Everolimus—Myalgia—Dactinomycin—melanoma	4.63e-05	0.000739	CcSEcCtD
Everolimus—Bronchospasm—Docetaxel—melanoma	4.62e-05	0.000737	CcSEcCtD
Everolimus—Tremor—Temozolomide—melanoma	4.61e-05	0.000736	CcSEcCtD
Everolimus—Discomfort—Dactinomycin—melanoma	4.58e-05	0.00073	CcSEcCtD
Everolimus—Angina pectoris—Docetaxel—melanoma	4.57e-05	0.00073	CcSEcCtD
Everolimus—Ill-defined disorder—Temozolomide—melanoma	4.57e-05	0.000729	CcSEcCtD
Everolimus—Leukopenia—Carmustine—melanoma	4.56e-05	0.000727	CcSEcCtD
Everolimus—Anaemia—Temozolomide—melanoma	4.55e-05	0.000726	CcSEcCtD
Everolimus—Anorexia—Bleomycin—melanoma	4.54e-05	0.000724	CcSEcCtD
Everolimus—Agitation—Temozolomide—melanoma	4.52e-05	0.000722	CcSEcCtD
Everolimus—Angioedema—Temozolomide—melanoma	4.5e-05	0.000718	CcSEcCtD
Everolimus—Pancytopenia—Docetaxel—melanoma	4.46e-05	0.000712	CcSEcCtD
Everolimus—Hypotension—Bleomycin—melanoma	4.45e-05	0.00071	CcSEcCtD
Everolimus—Oedema—Dactinomycin—melanoma	4.44e-05	0.000709	CcSEcCtD
Everolimus—Malaise—Temozolomide—melanoma	4.44e-05	0.000708	CcSEcCtD
Everolimus—Convulsion—Carmustine—melanoma	4.41e-05	0.000704	CcSEcCtD
Everolimus—Infection—Dactinomycin—melanoma	4.41e-05	0.000704	CcSEcCtD
Everolimus—Leukopenia—Temozolomide—melanoma	4.4e-05	0.000703	CcSEcCtD
Everolimus—Hypertension—Carmustine—melanoma	4.4e-05	0.000702	CcSEcCtD
Everolimus—Neutropenia—Docetaxel—melanoma	4.39e-05	0.000701	CcSEcCtD
Everolimus—Palpitations—Temozolomide—melanoma	4.35e-05	0.000694	CcSEcCtD
Everolimus—Thrombocytopenia—Dactinomycin—melanoma	4.35e-05	0.000694	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Bleomycin—melanoma	4.34e-05	0.000692	CcSEcCtD
Everolimus—Chest pain—Carmustine—melanoma	4.33e-05	0.000692	CcSEcCtD
Everolimus—Myalgia—Carmustine—melanoma	4.33e-05	0.000692	CcSEcCtD
Everolimus—Anxiety—Carmustine—melanoma	4.32e-05	0.000689	CcSEcCtD
Everolimus—Cough—Temozolomide—melanoma	4.29e-05	0.000685	CcSEcCtD
Everolimus—Paraesthesia—Bleomycin—melanoma	4.27e-05	0.000682	CcSEcCtD
Everolimus—Convulsion—Temozolomide—melanoma	4.26e-05	0.00068	CcSEcCtD
Everolimus—Weight decreased—Docetaxel—melanoma	4.25e-05	0.000678	CcSEcCtD
Everolimus—Hypertension—Temozolomide—melanoma	4.25e-05	0.000678	CcSEcCtD
Everolimus—Dyspnoea—Bleomycin—melanoma	4.24e-05	0.000677	CcSEcCtD
Everolimus—Anorexia—Dactinomycin—melanoma	4.23e-05	0.000675	CcSEcCtD
Everolimus—Pneumonia—Docetaxel—melanoma	4.21e-05	0.000672	CcSEcCtD
Everolimus—Arthralgia—Temozolomide—melanoma	4.19e-05	0.000669	CcSEcCtD
Everolimus—Myalgia—Temozolomide—melanoma	4.19e-05	0.000669	CcSEcCtD
Everolimus—Infestation NOS—Docetaxel—melanoma	4.19e-05	0.000668	CcSEcCtD
Everolimus—Infestation—Docetaxel—melanoma	4.19e-05	0.000668	CcSEcCtD
Everolimus—Anxiety—Temozolomide—melanoma	4.17e-05	0.000666	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	4.16e-05	0.000664	CcSEcCtD
Everolimus—Oedema—Carmustine—melanoma	4.16e-05	0.000663	CcSEcCtD
Everolimus—Discomfort—Temozolomide—melanoma	4.14e-05	0.000661	CcSEcCtD
Everolimus—Decreased appetite—Bleomycin—melanoma	4.14e-05	0.00066	CcSEcCtD
Everolimus—Infection—Carmustine—melanoma	4.13e-05	0.000659	CcSEcCtD
Everolimus—Acute coronary syndrome—Docetaxel—melanoma	4.13e-05	0.000659	CcSEcCtD
Everolimus—Renal failure—Docetaxel—melanoma	4.12e-05	0.000657	CcSEcCtD
Everolimus—Myocardial infarction—Docetaxel—melanoma	4.1e-05	0.000655	CcSEcCtD
Everolimus—Dry mouth—Temozolomide—melanoma	4.1e-05	0.000654	CcSEcCtD
Everolimus—Jaundice—Docetaxel—melanoma	4.08e-05	0.000651	CcSEcCtD
Everolimus—Stomatitis—Docetaxel—melanoma	4.08e-05	0.000651	CcSEcCtD
Everolimus—Pain—Bleomycin—melanoma	4.07e-05	0.00065	CcSEcCtD
Everolimus—Conjunctivitis—Docetaxel—melanoma	4.07e-05	0.00065	CcSEcCtD
Everolimus—Thrombocytopenia—Carmustine—melanoma	4.07e-05	0.000649	CcSEcCtD
Everolimus—Tachycardia—Carmustine—melanoma	4.06e-05	0.000647	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Dactinomycin—melanoma	4.04e-05	0.000646	CcSEcCtD
Everolimus—Oedema—Temozolomide—melanoma	4.02e-05	0.000641	CcSEcCtD
Everolimus—Infection—Temozolomide—melanoma	3.99e-05	0.000637	CcSEcCtD
Everolimus—Anorexia—Carmustine—melanoma	3.96e-05	0.000632	CcSEcCtD
Everolimus—Hepatobiliary disease—Docetaxel—melanoma	3.96e-05	0.000632	CcSEcCtD
Everolimus—Epistaxis—Docetaxel—melanoma	3.95e-05	0.00063	CcSEcCtD
Everolimus—Nervous system disorder—Temozolomide—melanoma	3.94e-05	0.000628	CcSEcCtD
Everolimus—Thrombocytopenia—Temozolomide—melanoma	3.93e-05	0.000627	CcSEcCtD
Everolimus—Feeling abnormal—Bleomycin—melanoma	3.92e-05	0.000626	CcSEcCtD
Everolimus—Skin disorder—Temozolomide—melanoma	3.9e-05	0.000623	CcSEcCtD
Everolimus—Hypotension—Carmustine—melanoma	3.88e-05	0.00062	CcSEcCtD
Everolimus—Hyperhidrosis—Temozolomide—melanoma	3.88e-05	0.00062	CcSEcCtD
Everolimus—Decreased appetite—Dactinomycin—melanoma	3.86e-05	0.000616	CcSEcCtD
Everolimus—Fatigue—Dactinomycin—melanoma	3.83e-05	0.000611	CcSEcCtD
Everolimus—Anorexia—Temozolomide—melanoma	3.83e-05	0.000611	CcSEcCtD
Everolimus—Pain—Dactinomycin—melanoma	3.8e-05	0.000606	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Carmustine—melanoma	3.79e-05	0.000604	CcSEcCtD
Everolimus—Haemoglobin—Docetaxel—melanoma	3.78e-05	0.000603	CcSEcCtD
Everolimus—Rhinitis—Docetaxel—melanoma	3.77e-05	0.000601	CcSEcCtD
Everolimus—Body temperature increased—Bleomycin—melanoma	3.76e-05	0.000601	CcSEcCtD
Everolimus—Haemorrhage—Docetaxel—melanoma	3.76e-05	0.0006	CcSEcCtD
Everolimus—Hepatitis—Docetaxel—melanoma	3.76e-05	0.0006	CcSEcCtD
Everolimus—Insomnia—Carmustine—melanoma	3.76e-05	0.0006	CcSEcCtD
Everolimus—Hypoaesthesia—Docetaxel—melanoma	3.74e-05	0.000597	CcSEcCtD
Everolimus—Paraesthesia—Carmustine—melanoma	3.73e-05	0.000595	CcSEcCtD
Everolimus—Pharyngitis—Docetaxel—melanoma	3.73e-05	0.000595	CcSEcCtD
Everolimus—Urinary tract disorder—Docetaxel—melanoma	3.71e-05	0.000592	CcSEcCtD
Everolimus—Dyspnoea—Carmustine—melanoma	3.7e-05	0.000591	CcSEcCtD
Everolimus—Oedema peripheral—Docetaxel—melanoma	3.7e-05	0.000591	CcSEcCtD
Everolimus—Somnolence—Carmustine—melanoma	3.69e-05	0.00059	CcSEcCtD
Everolimus—Connective tissue disorder—Docetaxel—melanoma	3.69e-05	0.000589	CcSEcCtD
Everolimus—Urethral disorder—Docetaxel—melanoma	3.68e-05	0.000588	CcSEcCtD
Everolimus—Feeling abnormal—Dactinomycin—melanoma	3.66e-05	0.000584	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Temozolomide—melanoma	3.66e-05	0.000584	CcSEcCtD
Everolimus—Insomnia—Temozolomide—melanoma	3.63e-05	0.00058	CcSEcCtD
Everolimus—Gastrointestinal pain—Dactinomycin—melanoma	3.63e-05	0.000579	CcSEcCtD
Everolimus—Decreased appetite—Carmustine—melanoma	3.61e-05	0.000576	CcSEcCtD
Everolimus—Paraesthesia—Temozolomide—melanoma	3.61e-05	0.000575	CcSEcCtD
Everolimus—Gastrointestinal disorder—Carmustine—melanoma	3.59e-05	0.000573	CcSEcCtD
Everolimus—Dyspnoea—Temozolomide—melanoma	3.58e-05	0.000571	CcSEcCtD
Everolimus—Somnolence—Temozolomide—melanoma	3.57e-05	0.00057	CcSEcCtD
Everolimus—Pain—Carmustine—melanoma	3.55e-05	0.000567	CcSEcCtD
Everolimus—Constipation—Carmustine—melanoma	3.55e-05	0.000567	CcSEcCtD
Everolimus—Dyspepsia—Temozolomide—melanoma	3.53e-05	0.000564	CcSEcCtD
Everolimus—Eye disorder—Docetaxel—melanoma	3.51e-05	0.000561	CcSEcCtD
Everolimus—Abdominal pain—Dactinomycin—melanoma	3.51e-05	0.00056	CcSEcCtD
Everolimus—Body temperature increased—Dactinomycin—melanoma	3.51e-05	0.00056	CcSEcCtD
Everolimus—Hypersensitivity—Bleomycin—melanoma	3.51e-05	0.00056	CcSEcCtD
Everolimus—Decreased appetite—Temozolomide—melanoma	3.49e-05	0.000557	CcSEcCtD
Everolimus—Flushing—Docetaxel—melanoma	3.49e-05	0.000557	CcSEcCtD
Everolimus—Cardiac disorder—Docetaxel—melanoma	3.49e-05	0.000557	CcSEcCtD
Everolimus—Gastrointestinal disorder—Temozolomide—melanoma	3.47e-05	0.000553	CcSEcCtD
Everolimus—Fatigue—Temozolomide—melanoma	3.46e-05	0.000553	CcSEcCtD
Everolimus—Pain—Temozolomide—melanoma	3.43e-05	0.000548	CcSEcCtD
Everolimus—Constipation—Temozolomide—melanoma	3.43e-05	0.000548	CcSEcCtD
Everolimus—Feeling abnormal—Carmustine—melanoma	3.42e-05	0.000546	CcSEcCtD
Everolimus—Asthenia—Bleomycin—melanoma	3.42e-05	0.000545	CcSEcCtD
Everolimus—Angiopathy—Docetaxel—melanoma	3.41e-05	0.000544	CcSEcCtD
Everolimus—Gastrointestinal pain—Carmustine—melanoma	3.4e-05	0.000542	CcSEcCtD
Everolimus—Immune system disorder—Docetaxel—melanoma	3.4e-05	0.000542	CcSEcCtD
Everolimus—Mediastinal disorder—Docetaxel—melanoma	3.39e-05	0.000541	CcSEcCtD
Everolimus—Chills—Docetaxel—melanoma	3.37e-05	0.000538	CcSEcCtD
Everolimus—Pruritus—Bleomycin—melanoma	3.37e-05	0.000538	CcSEcCtD
Everolimus—Alopecia—Docetaxel—melanoma	3.32e-05	0.00053	CcSEcCtD
Everolimus—Feeling abnormal—Temozolomide—melanoma	3.31e-05	0.000528	CcSEcCtD
Everolimus—Mental disorder—Docetaxel—melanoma	3.29e-05	0.000526	CcSEcCtD
Everolimus—Abdominal pain—Carmustine—melanoma	3.28e-05	0.000524	CcSEcCtD
Everolimus—Body temperature increased—Carmustine—melanoma	3.28e-05	0.000524	CcSEcCtD
Everolimus—Gastrointestinal pain—Temozolomide—melanoma	3.28e-05	0.000524	CcSEcCtD
Everolimus—Erythema—Docetaxel—melanoma	3.27e-05	0.000522	CcSEcCtD
Everolimus—Malnutrition—Docetaxel—melanoma	3.27e-05	0.000522	CcSEcCtD
Everolimus—Hypersensitivity—Dactinomycin—melanoma	3.27e-05	0.000522	CcSEcCtD
Everolimus—Dysgeusia—Docetaxel—melanoma	3.2e-05	0.000511	CcSEcCtD
Everolimus—Asthenia—Dactinomycin—melanoma	3.19e-05	0.000508	CcSEcCtD
Everolimus—Abdominal pain—Temozolomide—melanoma	3.17e-05	0.000507	CcSEcCtD
Everolimus—Body temperature increased—Temozolomide—melanoma	3.17e-05	0.000507	CcSEcCtD
Everolimus—Back pain—Docetaxel—melanoma	3.17e-05	0.000505	CcSEcCtD
Everolimus—Muscle spasms—Docetaxel—melanoma	3.15e-05	0.000502	CcSEcCtD
Everolimus—Hypersensitivity—Carmustine—melanoma	3.06e-05	0.000489	CcSEcCtD
Everolimus—Diarrhoea—Dactinomycin—melanoma	3.04e-05	0.000485	CcSEcCtD
Everolimus—Vomiting—Bleomycin—melanoma	3.03e-05	0.000483	CcSEcCtD
Everolimus—Anaemia—Docetaxel—melanoma	3.02e-05	0.000483	CcSEcCtD
Everolimus—Rash—Bleomycin—melanoma	3e-05	0.000479	CcSEcCtD
Everolimus—Dermatitis—Bleomycin—melanoma	3e-05	0.000479	CcSEcCtD
Everolimus—Asthenia—Carmustine—melanoma	2.98e-05	0.000476	CcSEcCtD
Everolimus—Hypersensitivity—Temozolomide—melanoma	2.96e-05	0.000472	CcSEcCtD
Everolimus—Syncope—Docetaxel—melanoma	2.93e-05	0.000468	CcSEcCtD
Everolimus—Leukopenia—Docetaxel—melanoma	2.93e-05	0.000467	CcSEcCtD
Everolimus—Palpitations—Docetaxel—melanoma	2.89e-05	0.000461	CcSEcCtD
Everolimus—Asthenia—Temozolomide—melanoma	2.88e-05	0.00046	CcSEcCtD
Everolimus—Loss of consciousness—Docetaxel—melanoma	2.88e-05	0.000459	CcSEcCtD
Everolimus—Cough—Docetaxel—melanoma	2.86e-05	0.000456	CcSEcCtD
Everolimus—Diarrhoea—Carmustine—melanoma	2.84e-05	0.000454	CcSEcCtD
Everolimus—Pruritus—Temozolomide—melanoma	2.84e-05	0.000453	CcSEcCtD
Everolimus—Convulsion—Docetaxel—melanoma	2.84e-05	0.000452	CcSEcCtD
Everolimus—Nausea—Bleomycin—melanoma	2.83e-05	0.000451	CcSEcCtD
Everolimus—Hypertension—Docetaxel—melanoma	2.82e-05	0.000451	CcSEcCtD
Everolimus—Vomiting—Dactinomycin—melanoma	2.82e-05	0.000451	CcSEcCtD
Everolimus—Rash—Dactinomycin—melanoma	2.8e-05	0.000447	CcSEcCtD
Everolimus—Chest pain—Docetaxel—melanoma	2.79e-05	0.000445	CcSEcCtD
Everolimus—Myalgia—Docetaxel—melanoma	2.79e-05	0.000445	CcSEcCtD
Everolimus—Arthralgia—Docetaxel—melanoma	2.79e-05	0.000445	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	2.77e-05	0.000442	CcSEcCtD
Everolimus—Dizziness—Carmustine—melanoma	2.75e-05	0.000439	CcSEcCtD
Everolimus—Diarrhoea—Temozolomide—melanoma	2.75e-05	0.000438	CcSEcCtD
Everolimus—Dry mouth—Docetaxel—melanoma	2.72e-05	0.000435	CcSEcCtD
Everolimus—Oedema—Docetaxel—melanoma	2.67e-05	0.000426	CcSEcCtD
Everolimus—Dizziness—Temozolomide—melanoma	2.66e-05	0.000424	CcSEcCtD
Everolimus—Infection—Docetaxel—melanoma	2.65e-05	0.000423	CcSEcCtD
Everolimus—Vomiting—Carmustine—melanoma	2.64e-05	0.000422	CcSEcCtD
Everolimus—Nausea—Dactinomycin—melanoma	2.64e-05	0.000421	CcSEcCtD
Everolimus—Shock—Docetaxel—melanoma	2.63e-05	0.000419	CcSEcCtD
Everolimus—Rash—Carmustine—melanoma	2.62e-05	0.000418	CcSEcCtD
Everolimus—Nervous system disorder—Docetaxel—melanoma	2.62e-05	0.000418	CcSEcCtD
Everolimus—Dermatitis—Carmustine—melanoma	2.62e-05	0.000418	CcSEcCtD
Everolimus—Thrombocytopenia—Docetaxel—melanoma	2.61e-05	0.000417	CcSEcCtD
Everolimus—Tachycardia—Docetaxel—melanoma	2.61e-05	0.000416	CcSEcCtD
Everolimus—Headache—Carmustine—melanoma	2.6e-05	0.000415	CcSEcCtD
Everolimus—Skin disorder—Docetaxel—melanoma	2.59e-05	0.000414	CcSEcCtD
Everolimus—Vomiting—Temozolomide—melanoma	2.55e-05	0.000407	CcSEcCtD
Everolimus—Anorexia—Docetaxel—melanoma	2.55e-05	0.000406	CcSEcCtD
Everolimus—Rash—Temozolomide—melanoma	2.53e-05	0.000404	CcSEcCtD
Everolimus—Dermatitis—Temozolomide—melanoma	2.53e-05	0.000404	CcSEcCtD
Everolimus—Headache—Temozolomide—melanoma	2.52e-05	0.000401	CcSEcCtD
Everolimus—Hypotension—Docetaxel—melanoma	2.5e-05	0.000398	CcSEcCtD
Everolimus—Nausea—Carmustine—melanoma	2.47e-05	0.000394	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Docetaxel—melanoma	2.43e-05	0.000388	CcSEcCtD
Everolimus—Insomnia—Docetaxel—melanoma	2.42e-05	0.000385	CcSEcCtD
Everolimus—Paraesthesia—Docetaxel—melanoma	2.4e-05	0.000383	CcSEcCtD
Everolimus—Nausea—Temozolomide—melanoma	2.39e-05	0.000381	CcSEcCtD
Everolimus—Dyspnoea—Docetaxel—melanoma	2.38e-05	0.00038	CcSEcCtD
Everolimus—Somnolence—Docetaxel—melanoma	2.37e-05	0.000379	CcSEcCtD
Everolimus—Dyspepsia—Docetaxel—melanoma	2.35e-05	0.000375	CcSEcCtD
Everolimus—Decreased appetite—Docetaxel—melanoma	2.32e-05	0.00037	CcSEcCtD
Everolimus—Gastrointestinal disorder—Docetaxel—melanoma	2.31e-05	0.000368	CcSEcCtD
Everolimus—Fatigue—Docetaxel—melanoma	2.3e-05	0.000367	CcSEcCtD
Everolimus—Pain—Docetaxel—melanoma	2.28e-05	0.000364	CcSEcCtD
Everolimus—Constipation—Docetaxel—melanoma	2.28e-05	0.000364	CcSEcCtD
Everolimus—Feeling abnormal—Docetaxel—melanoma	2.2e-05	0.000351	CcSEcCtD
Everolimus—Gastrointestinal pain—Docetaxel—melanoma	2.18e-05	0.000349	CcSEcCtD
Everolimus—Abdominal pain—Docetaxel—melanoma	2.11e-05	0.000337	CcSEcCtD
Everolimus—Body temperature increased—Docetaxel—melanoma	2.11e-05	0.000337	CcSEcCtD
Everolimus—Hypersensitivity—Docetaxel—melanoma	1.97e-05	0.000314	CcSEcCtD
Everolimus—Asthenia—Docetaxel—melanoma	1.92e-05	0.000306	CcSEcCtD
Everolimus—Pruritus—Docetaxel—melanoma	1.89e-05	0.000302	CcSEcCtD
Everolimus—Diarrhoea—Docetaxel—melanoma	1.83e-05	0.000292	CcSEcCtD
Everolimus—Dizziness—Docetaxel—melanoma	1.77e-05	0.000282	CcSEcCtD
Everolimus—Vomiting—Docetaxel—melanoma	1.7e-05	0.000271	CcSEcCtD
Everolimus—Rash—Docetaxel—melanoma	1.68e-05	0.000269	CcSEcCtD
Everolimus—Dermatitis—Docetaxel—melanoma	1.68e-05	0.000268	CcSEcCtD
Everolimus—Headache—Docetaxel—melanoma	1.67e-05	0.000267	CcSEcCtD
Everolimus—Nausea—Docetaxel—melanoma	1.59e-05	0.000253	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—GNA11—melanoma	5.3e-06	0.0001	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FLT1—melanoma	5.28e-06	9.95e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FN1—melanoma	5.21e-06	9.83e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFRA—melanoma	5.17e-06	9.74e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-A—melanoma	5.15e-06	9.71e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1B—melanoma	5.14e-06	9.7e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—RAC1—melanoma	5.13e-06	9.68e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1B—melanoma	5.12e-06	9.66e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PRKCA—melanoma	5.11e-06	9.64e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH1—melanoma	5.1e-06	9.62e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—ERCC2—melanoma	5.07e-06	9.56e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—melanoma	5.06e-06	9.54e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAP2K2—melanoma	5e-06	9.43e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CD80—melanoma	5e-06	9.42e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIT—melanoma	4.99e-06	9.4e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—melanoma	4.99e-06	9.4e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—melanoma	4.99e-06	9.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HDAC2—melanoma	4.98e-06	9.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO4—melanoma	4.98e-06	9.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCR4—melanoma	4.98e-06	9.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—melanoma	4.98e-06	9.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HS3ST5—melanoma	4.97e-06	9.37e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—melanoma	4.94e-06	9.32e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—melanoma	4.93e-06	9.3e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGF—melanoma	4.93e-06	9.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNAQ—melanoma	4.93e-06	9.29e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFKB1—melanoma	4.91e-06	9.25e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—melanoma	4.84e-06	9.12e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TERT—melanoma	4.75e-06	8.96e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HLA-A—melanoma	4.75e-06	8.96e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—melanoma	4.75e-06	8.95e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—RAC1—melanoma	4.74e-06	8.94e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—melanoma	4.74e-06	8.93e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—melanoma	4.73e-06	8.91e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—melanoma	4.72e-06	8.89e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NFKB1—melanoma	4.71e-06	8.89e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—melanoma	4.71e-06	8.88e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DRB1—melanoma	4.7e-06	8.87e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BRAF—melanoma	4.69e-06	8.84e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SYK—melanoma	4.63e-06	8.74e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—melanoma	4.57e-06	8.61e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NGFR—melanoma	4.55e-06	8.58e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT3—melanoma	4.55e-06	8.58e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ITGAV—melanoma	4.55e-06	8.58e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HIF1A—melanoma	4.55e-06	8.57e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—melanoma	4.51e-06	8.51e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAP2K1—melanoma	4.41e-06	8.32e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—melanoma	4.4e-06	8.3e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—melanoma	4.38e-06	8.27e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD80—melanoma	4.35e-06	8.19e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIT—melanoma	4.34e-06	8.18e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGF—melanoma	4.29e-06	8.09e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—melanoma	4.23e-06	7.97e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—melanoma	4.22e-06	7.95e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK3—melanoma	4.21e-06	7.95e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS1—melanoma	4.21e-06	7.94e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—melanoma	4.21e-06	7.93e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—S100B—melanoma	4.2e-06	7.92e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF2—melanoma	4.2e-06	7.91e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—melanoma	4.14e-06	7.8e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOTCH1—melanoma	4.1e-06	7.72e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—melanoma	4.04e-06	7.62e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK3—melanoma	4.03e-06	7.6e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB4—melanoma	4.02e-06	7.58e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CD80—melanoma	4.01e-06	7.57e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK1—melanoma	4.01e-06	7.56e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—melanoma	4.01e-06	7.56e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—melanoma	4.01e-06	7.55e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—melanoma	4.01e-06	7.55e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—melanoma	3.99e-06	7.53e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN2B—melanoma	3.98e-06	7.51e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGF—melanoma	3.96e-06	7.46e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MDM2—melanoma	3.93e-06	7.41e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—melanoma	3.92e-06	7.39e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—melanoma	3.87e-06	7.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CD86—melanoma	3.85e-06	7.26e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—melanoma	3.85e-06	7.26e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAP2K1—melanoma	3.84e-06	7.24e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK1—melanoma	3.83e-06	7.23e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—melanoma	3.83e-06	7.23e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—melanoma	3.82e-06	7.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—melanoma	3.82e-06	7.21e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—melanoma	3.81e-06	7.19e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—melanoma	3.79e-06	7.14e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—melanoma	3.76e-06	7.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCB4—melanoma	3.76e-06	7.1e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CSF2—melanoma	3.73e-06	7.04e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF1—melanoma	3.73e-06	7.04e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—melanoma	3.67e-06	6.92e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—E2F1—melanoma	3.66e-06	6.89e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF2—melanoma	3.65e-06	6.88e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—melanoma	3.64e-06	6.86e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—melanoma	3.62e-06	6.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFRA—melanoma	3.62e-06	6.82e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—melanoma	3.59e-06	6.76e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ITGB3—melanoma	3.58e-06	6.75e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCA—melanoma	3.58e-06	6.75e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAP2K1—melanoma	3.54e-06	6.68e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIP4K2A—melanoma	3.54e-06	6.67e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC6A11—melanoma	3.54e-06	6.67e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CD—melanoma	3.52e-06	6.64e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—melanoma	3.51e-06	6.63e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SPP1—melanoma	3.51e-06	6.62e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—melanoma	3.51e-06	6.62e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAP2K2—melanoma	3.5e-06	6.6e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—melanoma	3.48e-06	6.56e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—melanoma	3.47e-06	6.54e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTAP—melanoma	3.44e-06	6.49e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—melanoma	3.44e-06	6.48e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—melanoma	3.42e-06	6.45e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MDM2—melanoma	3.42e-06	6.44e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—melanoma	3.39e-06	6.39e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF2—melanoma	3.37e-06	6.36e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—melanoma	3.37e-06	6.35e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—melanoma	3.34e-06	6.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—melanoma	3.33e-06	6.28e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—melanoma	3.33e-06	6.27e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—melanoma	3.32e-06	6.27e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—melanoma	3.32e-06	6.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAC1—melanoma	3.32e-06	6.26e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—melanoma	3.32e-06	6.26e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—melanoma	3.31e-06	6.24e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—melanoma	3.3e-06	6.23e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NFKB1—melanoma	3.29e-06	6.2e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—melanoma	3.22e-06	6.07e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—melanoma	3.18e-06	6e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MDM2—melanoma	3.15e-06	5.95e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1B—melanoma	3.12e-06	5.88e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—melanoma	3.11e-06	5.86e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—melanoma	3.09e-06	5.83e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—melanoma	3.08e-06	5.81e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—melanoma	3.08e-06	5.8e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—melanoma	3.07e-06	5.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PHGDH—melanoma	3.07e-06	5.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LUM—melanoma	3.07e-06	5.79e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—melanoma	3.06e-06	5.78e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—melanoma	3.05e-06	5.76e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—melanoma	3.04e-06	5.74e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—melanoma	3.04e-06	5.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HPSE—melanoma	3.01e-06	5.67e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—melanoma	2.98e-06	5.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CUBN—melanoma	2.95e-06	5.57e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—melanoma	2.95e-06	5.57e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—melanoma	2.95e-06	5.56e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—melanoma	2.95e-06	5.55e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—melanoma	2.95e-06	5.55e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FN1—melanoma	2.93e-06	5.53e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—melanoma	2.88e-06	5.43e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—melanoma	2.88e-06	5.43e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—melanoma	2.87e-06	5.42e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—melanoma	2.87e-06	5.41e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NFKB1—melanoma	2.86e-06	5.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDHD—melanoma	2.85e-06	5.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CSPG4—melanoma	2.85e-06	5.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BSG—melanoma	2.85e-06	5.38e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—melanoma	2.84e-06	5.36e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK3—melanoma	2.82e-06	5.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CD80—melanoma	2.81e-06	5.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—melanoma	2.8e-06	5.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—melanoma	2.8e-06	5.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—melanoma	2.8e-06	5.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGF—melanoma	2.77e-06	5.23e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPAM—melanoma	2.76e-06	5.21e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—melanoma	2.74e-06	5.17e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—melanoma	2.73e-06	5.15e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—melanoma	2.72e-06	5.13e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—melanoma	2.72e-06	5.12e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK1—melanoma	2.68e-06	5.06e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—melanoma	2.68e-06	5.06e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—melanoma	2.66e-06	5.01e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—melanoma	2.65e-06	5e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—melanoma	2.64e-06	4.97e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—melanoma	2.57e-06	4.84e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—melanoma	2.57e-06	4.84e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—melanoma	2.56e-06	4.83e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—melanoma	2.54e-06	4.78e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAP2K1—melanoma	2.48e-06	4.68e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—melanoma	2.47e-06	4.65e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK3—melanoma	2.45e-06	4.63e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—melanoma	2.37e-06	4.47e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—melanoma	2.37e-06	4.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF2—melanoma	2.36e-06	4.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G6—melanoma	2.35e-06	4.43e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK1—melanoma	2.34e-06	4.4e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—melanoma	2.33e-06	4.4e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—melanoma	2.33e-06	4.39e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK3—melanoma	2.27e-06	4.27e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—melanoma	2.25e-06	4.25e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MDM2—melanoma	2.21e-06	4.16e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—melanoma	2.21e-06	4.16e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—melanoma	2.2e-06	4.16e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—melanoma	2.18e-06	4.11e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK1—melanoma	2.16e-06	4.07e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—melanoma	2.16e-06	4.06e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—melanoma	2.16e-06	4.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—melanoma	2.15e-06	4.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—VCAN—melanoma	2.11e-06	3.98e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—melanoma	2.07e-06	3.89e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—melanoma	2.06e-06	3.89e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—melanoma	2.04e-06	3.84e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—melanoma	2.03e-06	3.82e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—melanoma	2.02e-06	3.8e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—melanoma	1.98e-06	3.73e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—melanoma	1.97e-06	3.72e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—melanoma	1.92e-06	3.63e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—melanoma	1.91e-06	3.59e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—melanoma	1.9e-06	3.59e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—melanoma	1.87e-06	3.53e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—melanoma	1.87e-06	3.53e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—melanoma	1.87e-06	3.52e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—melanoma	1.86e-06	3.51e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—melanoma	1.86e-06	3.5e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKB1—melanoma	1.85e-06	3.48e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—melanoma	1.79e-06	3.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP17A1—melanoma	1.78e-06	3.36e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—melanoma	1.73e-06	3.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNA11—melanoma	1.68e-06	3.17e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—melanoma	1.68e-06	3.16e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—melanoma	1.66e-06	3.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—melanoma	1.66e-06	3.12e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—melanoma	1.66e-06	3.12e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—melanoma	1.66e-06	3.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FASN—melanoma	1.65e-06	3.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC5A5—melanoma	1.62e-06	3.05e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK3—melanoma	1.59e-06	2.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD44—melanoma	1.56e-06	2.95e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNAQ—melanoma	1.56e-06	2.95e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—melanoma	1.54e-06	2.91e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—melanoma	1.53e-06	2.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK1—melanoma	1.51e-06	2.85e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—melanoma	1.51e-06	2.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1B1—melanoma	1.5e-06	2.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—melanoma	1.43e-06	2.69e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—melanoma	1.31e-06	2.47e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—melanoma	1.27e-06	2.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—melanoma	1.23e-06	2.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—melanoma	1.21e-06	2.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—melanoma	1.16e-06	2.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PRKCA—melanoma	1.14e-06	2.14e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ERCC2—melanoma	1.13e-06	2.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—melanoma	1.07e-06	2.02e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—melanoma	8.9e-07	1.68e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—melanoma	8.59e-07	1.62e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—melanoma	7.82e-07	1.47e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—melanoma	7.72e-07	1.46e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—melanoma	6.82e-07	1.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—melanoma	6.75e-07	1.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—melanoma	5.89e-07	1.11e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—melanoma	4.16e-07	7.84e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—melanoma	3.39e-07	6.4e-06	CbGpPWpGaD
